We are in the engineering phase of planning several large, high potency manufacturing plants in both the US and China, through public/private partnerships executed in both markets. Our architect’s design for the US plant is shown in the photo on the left.
In the US our plans include a 320,000 sq ft cGMP fill-finish high potency oncology plant capable of manufacturing sterile injectable and oral solid dosage forms. We have also established a 50,000 sq ft North American Headquarters. In early 2016 Andrew Cuomo, the Governor of New York, announced our public/private partnership with New York State and held a ribbon cutting ceremony in our North American Headquarters along with local government elected officials.
In Chongqing China, where we have an existing active pharmaceutical ingredient plant, we are designing an expanded active pharmaceutical ingredient plant and a fill-finish plant and logistics center totaling about 500,000 sq ft. These facilities will provide us valuable and necessary access to the Chinese cancer market. Our public/private partnership with Chongqing was announced in October 2015 with a signing ceremony in Banan, Chongqing attended by local government officials and the Athenex Board and Management team.